

9 March 2020

**Medannex announces new immunomodulatory approach
to cancer treatment at Nature conference**

Medannex Ltd (Edinburgh) today announced the presentation of new data on their proprietary immunomodulatory agent, MDX-124, a humanised monoclonal antibody with significant therapeutic potential in oncology. The Scottish biopharmaceutical company has been invited to present pre-clinical data at the Nature Reviews Cancer Conference in Salt Lake City this week.

MDX-124 targets and inhibits annexin-A1, a protein that modulates the immune system and plays a key role in the development of many cancers. MDX-124 is a novel immunomodulatory agent with an anti-proliferative effect. It has been shown to reduce cancer cell growth by up to 76%, in a broad range of cell lines including breast, colorectal, pancreatic and ovarian cancer. Furthermore, in an experimental model of triple negative breast cancer, MDX-124 has been shown to markedly reduce tumour volume.

Medannex Chief Executive Officer, Ian Abercrombie, said: “We’re delighted to share our exciting data at the Nature conference, showing how our novel antibody suppresses cancer cell growth through the targeted inhibition of annexin-A1. MDX-124 has the potential to make a significant impact in the treatment of numerous cancers, many of which are poorly responsive to current immuno-oncology agents. We are currently completing IND-enabling testing in preparation for our First-in-Human clinical study.”

The data, co-authored by Medannex and its collaborators at ARU (Cambridge, UK) will be presented at ‘Transdisciplinary Cancer Interception: Leveraging Biology to Improve Prevention and Detection’ at the Huntsman Cancer Institute, University of Utah on 10 March 2020.

- ENDS -

About Medannex Ltd: Medannex is a privately-owned, development-stage biopharmaceutical company registered in Scotland, with headquarters in Edinburgh. The company is developing novel treatments to improve the lives of people suffering from cancers and autoimmune diseases. Medannex has generated encouraging pre-clinical data, which allowed the company to close an £11m Series B funding round in 2019, led by Boston-based global Life Sciences investor Morningside Ventures and supported by the Scottish Investment Bank. For more information, visit: <https://medannex.org>

Medannex Ltd press enquiries – email jamesingham@medannex.org